Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07119931) titled 'A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)' on Aug. 6.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital
Condition:
HCC
Intervention:
Drug: lparomlimab and Tuvonralimab Injection in Combination with HAIC and bevacizumab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of F...